Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug
Bristol-Myers Squibb. "Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma."
Bayer. "OCEANIC-AF study stopped early due to lack of efficacy."
- Bristol-Myers Squibb and 2seventy bio shares dropped after the FDA said it would not make a decision on expanded use of the companies' cancer drug next month.
- The treatment has already been approved by regulators to treat adults who haven't responded to other medicines.
- A decision by …